Business Context and Reporting Period
West Pharmaceutical Services, Inc. filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2020. The company manufactures containment, packaging, delivery systems and contract-manufactured devices for pharmaceutical, biologic, generic, diagnostic and medical-device customers. Operations are reported through Proprietary Products and Contract-Manufactured Products.
Financial Performance and Liquidity
| Metric | Q3 2020 | Q3 2019 | 9M 2020 | 9M 2019 |
|---|---|---|---|---|
| Net sales | $548.0 million | $456.1 million | $1,566.7 million | $1,369.3 million |
| Gross profit | $194.6 million | $147.8 million | $556.7 million | $452.5 million |
| Gross margin | 35.5% | 32.4% | 35.5% | 33.0% |
| Operating profit | $99.2 million | $67.3 million | $290.8 million | $218.5 million |
| Operating margin | 18.1% | 14.8% | 18.6% | 16.0% |
| Net income | $82.3 million | $56.3 million | $247.8 million | $177.8 million |
| Diluted EPS | $1.09 | $0.75 | $3.28 | $2.36 |
- Q3 net sales increased 20.1%; organic growth excluding currency effects was 18.2%. Nine-month sales increased 14.4%, or 15.1% organically excluding currency and the South Korea acquisition.
- Q3 Proprietary Products sales rose 22.1% as reported and 20.3% organically; Contract-Manufactured Products sales rose 14.0% as reported and 11.7% organically.
- COVID-19-related activity contributed approximately $32 million to Q3 Proprietary Products sales and approximately $52 million for the nine-month period, primarily involving antiviral treatments and treatment of underlying COVID-19 symptoms.
- Cash provided by operations was $323.8 million for the first nine months, compared with $260.8 million in the prior-year period. Capital expenditures were $116.7 million.
- Cash and cash equivalents were $519.4 million at September 30, 2020, compared with $439.1 million at December 31, 2019. Working capital was $790.6 million.
- Total debt was $255.7 million, including $253.4 million of long-term debt. No borrowings were outstanding under the revolving credit facility; available capacity, net of $2.5 million of letters of credit, was $297.5 million.
- The company repurchased 761,500 shares for $115.5 million during the first nine months and paid $35.5 million of dividends.
Material Changes Versus the Prior Comparable Period
- Profitability improved substantially, with Q3 operating profit up 47.4% and nine-month operating profit up 33.1%. Growth was led by Proprietary Products, favorable product mix, pricing and production efficiencies.
- Gross margin expanded by 3.1 percentage points in Q3 and 2.5 percentage points for the nine-month period. SG&A declined as a percentage of sales to 13.9% in Q3 from 14.2% and to 14.4% for nine months from 14.9%.
- R&D expense increased 34.4% in Q3 and 18.5% for nine months, reflecting continued investment in self-injection systems, fluid-transfer devices, elastomeric components and formulation development.
- The effective tax rate increased to 21.6% in Q3 from 16.8%, but declined to 18.2% for nine months from 19.8%, primarily due to changes in stock-based compensation deductions.
- Corporate SG&A increased materially, rising 52.1% in Q3 and 42.3% for nine months, primarily from higher compensation costs.
- Operating cash flow increased by $63.0 million, while investing cash use increased by $14.5 million and financing cash use increased by $40.6 million, principally because of higher share repurchases.
Guidance, Outlook, Commentary, Risks and Unusual Items
- The filing does not provide specific full-year revenue, earnings or EPS guidance. Management states that cash on hand, operating cash flow and revolving-credit availability should meet foreseeable liquidity needs.
- Manufacturing facilities continued operating during the COVID-19 pandemic, with enhanced safety measures and higher production at certain locations. Management stated that remote work and travel restrictions had limited operational impact through the reporting period.
- Management cautioned that future COVID-19 effects remain uncertain and could affect employees, suppliers, customers, transportation, demand, production costs and supply-chain continuity.
- A July 2020 restructuring plan is expected to require approximately $15 million to $17 million of charges over up to 24 months. The company recorded $4.5 million of related severance charges through September 30.
- Fixed-asset impairment charges were $7.2 million for the first nine months, compared with $2.3 million in the prior-year period. SmartDose contingent-consideration expense was $0.9 million for nine months, and the related liability was $3.5 million at September 30.
- The company received FDA market clearance on October 21, 2020 for the Vial2BagAdvanced 20mm Admixture Device, following the earlier Vial2Bag product recall related to potential unpredictable or variable dosing.
- Principal disclosed risks include COVID-19 and other supply-chain disruptions, customer demand and inventory changes, competition and pricing pressure, regulatory approval and commercialization of customer products, reliance on suppliers and affiliates, foreign-exchange volatility, commodity costs, skilled-labor availability and healthcare legislation.
- There were no significant changes to previously disclosed commitments and contingencies, and management stated that current legal proceedings are not expected to have a material adverse effect. No legal proceedings were listed under Part II, Item 1.
Investor Verification Priorities
- Verify the sustainability of COVID-19-related sales and the extent to which demand reflects temporary inventory building or longer-term volume growth.
- Assess whether gross-margin expansion, production efficiencies and favorable product mix can continue after pandemic-related demand normalizes.
- Track the $15 million to $17 million restructuring plan, including remaining charges, timing and expected operating benefits.
- Review capital-expenditure requirements, inventory growth, share repurchases and dividend commitments relative to operating cash generation.
- Monitor the Vial2BagAdvanced commercialization and any remaining recall, regulatory or product-liability exposure.
- Evaluate exposure to foreign-exchange movements, petroleum-based raw-material costs, supply interruptions and reliance on key suppliers and affiliates.
- Confirm compliance with debt covenants and the availability of the $297.5 million revolving-credit capacity.